Nicolas Majunke

Learn More
Transcatheter closure of atrial septal defects (ASDs) was performed mainly in children and adolescents. Information about outcome and complications in adults was limited. From November 1997 to November 2005, percutaneous closure of ASDs using the Amplatzer septal occluder was attempted in 650 consecutive adult patients. Median patient age was 45.8 +/- 16.2(More)
Transcatheter closure of the left atrial appendage has been developed as an alternative to chronic oral anticoagulation for stroke prevention in patients with atrial fibrillation, and as a primary therapy for patients with contraindications to chronic oral anticoagulation. The promise of this new intervention compared with warfarin has been supported by(More)
AIMS To summarise our experiences of device closure of residual shunt after transcatheter closure of patent foramen ovale (PFO). METHODS AND RESULTS Since October 1997 implantation of a second closure device was attempted in 40 patients with a moderate or large residual shunt after implantation of a PFO closure device. The mean age of the patients was 51(More)
OBJECTIVES The purpose of this study was to evaluate the safety and effectiveness of the SeptRx patent foramen ovale (PFO) closure device (SeptRx, Inc., Fremont, California). BACKGROUND A PFO is a relatively common remnant of the fetal circulation that can be associated with cryptogenic stroke, transient ischemic attack, migraine, or decompression(More)
OBJECTIVES To determine the incidence of symptomatic recurrent embolic events after patent foramen ovale (PFO) closure and potential causes for these events. BACKGROUND It is well-known that cerebral or other embolic events may occur after PFO closure. METHODS This is a retrospective analysis of consecutive patients who underwent PFO closure for(More)
This randomized trial compared procedural complications and 30-day clinical outcomes of 3 patent foramen ovale (PFO) closure devices (Amplatzer, Helex, and CardioSEAL-STARflex). It examined 660 patients (361 men, 299 women, mean age 49.3+/-1.9 years), with 220 patients per group. All patients had a history of paradoxical embolism. All PFO closures were(More)
BACKGROUND Transcatheter left atrial appendage (LAA) closure is an alternative therapy for stroke prevention in atrial fibrillation (AF) patients. However; real-world efficacy, safety and complications have yet to be investigated. We sought to determine the procedural outcomes and potential complications of LAA closure in routine clinical practice at a(More)
Patent foramen ovale (PFO) is a congenital, small tunnel-like connection between the right and left atria that usually closes spontaneously after birth. However, frequently (in up to 35% of the normal population) it persists into adulthood. It is associated with 'paradoxical' embolism from the venous to the arterial system and may result in stroke or(More)
and ECV was 21.1 3.2% in athletes versus 28.5 2.3% in HCM subjects (p <0.001). AUCs to correctly detect HCM for native T1 and ECV were 0.938 (95% CI: 0.769 to 0.995) and 0.963 (95% CI: 0.805 to 0.999; p <0.001 for both). There were no significant differences between AUCs. The optimal cutoff values used to diagnose HCM were ECV >22.5% (sensitivity: 100%;(More)
OBJECTIVE To evaluate the effect of transcatheter closure of the left atrial appendage (LAA) with the Watchman device on the secretion of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). BACKGROUND The LAA plays an important role in the regulation of intravascular volume via release of ANP and BNP. To date, there are no data(More)